IP Library Granted Patent US 11,291,643
Granted Patent B2
US 11,291,643 · App. 16/819,845 · Granted Apr 5, 2022

Methods of treating hypertriglyceridemia

Inventors: Mehar Manku (Birmingham, GB); Ian Osterloh (Kent, GB); Pierre Wicker (Mystic, CT); Rene Braeckman (Richboro, PA); Paresh Soni (Mystic, CT)
Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
A61K31/232A61K31/202A61P3/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,291,643
App. No.
16/819,845
Granted
Apr 5, 2022
Kind
B2
Abstract

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Claims (10)

1. A method of reducing vLDL particle size in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl comprising administering to the subject about 4 g per day ethyl eicosapentaenoate thereby to produce a reduction in vLDL particle size.

2. The method of claim 1 wherein said reduction is statistically significant.

3. The method of claim 1 wherein administering to the subject about 4 g per day of ethyl eicosapentaenoate produces a reduction in vLDL particle size by comparison with a baseline vLDL particle size prior to initiation of administration.

4. The method of claim 3 wherein the reduction in vLDL particle size is at least a 2.5% reduction.

5. The method of claim 3 wherein the reduction in vLDL particle size is at least a 5% reduction.

6. The method of claim 3 wherein the reduction in vLDL particle size is at least a 8% reduction.

7. The method of claim 1 wherein the subject is administered about 3.8 g to about 4 g per day of ethyl eicosapentaenoate.

8. The method of claim 1 wherein the subject is administered ethyl eicosapentaenoate for a period of 12 weeks.

9. The method of claim 1 , wherein the ethyl eicosapentaenoate is administered to the subject 1 to 4 times per day.

10. The method of claim 1 , wherein the ethyl eicosapentaenoate is present in one or more capsules.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2020
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 052179/0460 →
Continuity (6)
Continuation 16436364 · Jun 10, 2019
Continuation 14936295 · Nov 9, 2015
Continuation 13671197 · Nov 7, 2012
Provisional Application 61666433 · Jun 29, 2012
Provisional Application 61556573 · Nov 7, 2011
Related Publication 20200215017A1 · Jul 9, 2020